Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics Inc demonstrates a positive outlook driven by strong clinical data from its pipeline products, particularly icotrokinra, which has shown significant improvements in clinical response and endoscopic outcomes over time. The strong business development track record and anticipated momentum from upcoming catalysts further enhance the company's growth potential, particularly as icotrokinra is poised to fill a market gap left by existing therapies. As the company prepares for a New Drug Application (NDA) submission for icotrokinra in July 2025, the promising efficacy and safety results position Protagonist Therapeutics favorably within the biopharmaceutical landscape.

Bears say

Protagonist Therapeutics faces significant risks that contribute to a negative outlook, primarily due to potential safety concerns arising from ongoing clinical trials, which could adversely affect its product development. The company also encounters competitive challenges that might lead to strategic partners deciding against further development of its lead candidate, Icotrokinra, as well as heightened regulatory and pricing risks that could impact market viability. Additionally, the ongoing need for future capital, combined with the risk of dilution for existing shareholders, presents financial uncertainties that could hinder the company’s operational stability.

Protagonist Therapeutics (PTGX) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 14 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.